欧林生物: 成都欧林生物科技股份有限公司前次募集资金使用情况专项报告

Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. reported on the usage of funds raised from its initial public offering, detailing the total amount raised, the current balance, and the allocation of these funds for various projects [1][2][3]. Fundraising Overview - The company raised a total of RMB 400,436,400.00 from the issuance of 40,530,000 shares at RMB 9.88 per share, with a net amount of RMB 358,837,273.38 after deducting issuance costs [1]. - As of March 31, 2025, the remaining balance of the raised funds is RMB 100,390,120.43, which accounts for 27.98% of the net amount raised [8]. Fund Storage Situation - The funds are stored in two bank accounts: - RMB 39,859,763.12 at China Merchants Bank - RMB 60,530,357.31 at Industrial Bank, totaling RMB 100,390,120.43 [2]. Actual Usage of Funds - The company has utilized RMB 27,752.20 million of the raised funds, with the following annual breakdown: - 2021: RMB 1,998.69 million - 2022: RMB 9,931.96 million [9]. - The company has adjusted the allocation of funds, redirecting RMB 10,278.30 million initially intended for vaccine projects to clinical research projects [3]. Temporary Idle Funds Management - The company has engaged in cash management for temporarily idle funds, with a maximum daily balance not exceeding RMB 30 million. The investment returns from cash management in 2021, 2022, and 2023 were RMB 3.4968 million, RMB 7.1798 million, and RMB 8.1850 million, respectively [5][6][7]. Economic Benefits from Investment Projects - The report includes a table detailing the economic benefits realized from the investment projects, although specific figures are not provided in the summary [9][12].